Business Description
Bolt Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US0977022039
Share Class Description:
BOLT: Ordinary SharesTotal Employee Number:
23Description
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.03 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 1.13 | |||||
Debt-to-EBITDA | -0.77 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -14.9 | |||||
Beneish M-Score | -1.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.3 | |||||
3-Year EBITDA Growth Rate | 27.8 | |||||
3-Year EPS without NRI Growth Rate | 28.8 | |||||
3-Year FCF Growth Rate | 20.2 | |||||
3-Year Book Growth Rate | -46.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -17.18 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.67 | |||||
9-Day RSI | 49.1 | |||||
14-Day RSI | 47.07 | |||||
3-1 Month Momentum % | 14 | |||||
6-1 Month Momentum % | -3.75 | |||||
12-1 Month Momentum % | -10.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.51 | |||||
Quick Ratio | 3.51 | |||||
Cash Ratio | 3.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | -18.13 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -463.44 | |||||
Net Margin % | -455.15 | |||||
EBITDA Margin % | -446.59 | |||||
FCF Margin % | -530.97 | |||||
OCF Margin % | -530.97 | |||||
ROE % | -90.14 | |||||
ROA % | -44.66 | |||||
ROIC % | -78.83 | |||||
3-Year ROIIC % | -169.55 | |||||
ROC (Joel Greenblatt) % | -140.87 | |||||
ROCE % | -53.87 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.25 | |||||
PB Ratio | 0.43 | |||||
Price-to-Tangible-Book | 0.43 | |||||
EV-to-EBIT | -0.26 | |||||
EV-to-EBITDA | -0.27 | |||||
EV-to-Revenue | 1.21 | |||||
EV-to-Forward-Revenue | 1.74 | |||||
EV-to-FCF | -0.23 | |||||
Price-to-GF-Value | 0.49 | |||||
Earnings Yield (Greenblatt) % | -384.62 | |||||
FCF Yield % | -407.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BOLT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bolt Biotherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.499 | ||
| EPS (TTM) ($) | -16.33 | ||
| Beta | 1.1521 | ||
| 3-Year Sharpe Ratio | -1.16 | ||
| 3-Year Sortino Ratio | -1.35 | ||
| Volatility % | 41.8 | ||
| 14-Day RSI | 47.07 | ||
| 14-Day ATR ($) | 0.361739 | ||
| 20-Day SMA ($) | 4.545755 | ||
| 12-1 Month Momentum % | -10.78 | ||
| 52-Week Range ($) | 3.75 - 7.1999 | ||
| Shares Outstanding (Mil) | 1.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bolt Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bolt Biotherapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 136 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 46 days | ||
| General meeting for 2026 | 2026-06-10 11:00 | 4.62 (-3.75%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 4.70 (-1.26%) | ||
| Annual report for 2025 | 2026-03-12 | 4.13 (-3.05%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 4.13 (-3.05%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-11 | 4.26 (-1.97%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 09:50 | 4.52 (-2.80%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 4.81 (-1.54%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 5.62 (+0.90%) |
Show
Entries
Bolt Biotherapeutics Inc Frequently Asked Questions
What is Bolt Biotherapeutics Inc(BOLT)'s stock price today?
The current price of BOLT is $4.41. The 52 week high of BOLT is $7.20 and 52 week low is $3.75.
When is next earnings date of Bolt Biotherapeutics Inc(BOLT)?
The next earnings date of Bolt Biotherapeutics Inc(BOLT) is 2026-08-14 Est..
Does Bolt Biotherapeutics Inc(BOLT) pay dividends? If so, how much?
Bolt Biotherapeutics Inc(BOLT) does not pay dividend.
Guru Commentaries on NAS:BOLT
No articles.
Press Release
Articles on Bolt Biotherapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers